肝细胞癌中的髓样细胞。
Myeloid cells in hepatocellular carcinoma.
作者信息
Wan Shanshan, Kuo Ning, Kryczek Ilona, Zou Weiping, Welling Theodore H
机构信息
Section of Transplantation, University of Michigan, Ann Arbor, MI.
Department of Surgery, University of Michigan, Ann Arbor, MI.
出版信息
Hepatology. 2015 Oct;62(4):1304-12. doi: 10.1002/hep.27867. Epub 2015 Jul 1.
Abstract
Hepatocellular carcinoma (HCC) is highly associated with inflammation. Myeloid cells, including tumor-associated macrophages and myeloid-derived suppressor cells, are abundant in the HCC microenvironment and are often associated with poor prognosis. Myeloid cells in HCC play a vital role in supporting tumor initiation, progression, angiogenesis, metastasis, and therapeutic resistance. Here, we summarize our current knowledge about myeloid cells in HCC and focus on their immune-suppressive activities and tumor-promoting functions, as well as the relevance to potential new therapies in HCC.
摘要
肝细胞癌（HCC）与炎症高度相关。髓系细胞，包括肿瘤相关巨噬细胞和髓系来源的抑制细胞，在HCC微环境中大量存在，且常与预后不良相关。HCC中的髓系细胞在支持肿瘤起始、进展、血管生成、转移和治疗抵抗方面发挥着至关重要的作用。在此，我们总结了目前关于HCC中髓系细胞的知识，并重点关注它们的免疫抑制活性和肿瘤促进功能，以及与HCC潜在新疗法的相关性。
相似文献
1
Myeloid cells in hepatocellular carcinoma.肝细胞癌中的髓样细胞。
Hepatology. 2015 Oct;62(4):1304-12. doi: 10.1002/hep.27867. Epub 2015 Jul 1.
2
Immune responses in hepatocellular carcinoma.肝细胞癌的免疫反应。
Dig Dis. 2010;28(1):150-4. doi: 10.1159/000282079. Epub 2010 May 7.
3
Hepatic myeloid-derived suppressor cells in cancer.癌症中的肝脏髓源性抑制细胞
Cancer Immunol Immunother. 2015 Aug;64(8):931-40. doi: 10.1007/s00262-015-1736-y. Epub 2015 Jul 2.
4
Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function.上调的髓源性抑制细胞通过损害树突状细胞功能促进肝细胞癌的发展。
Scand J Gastroenterol. 2011 Feb;46(2):156-64. doi: 10.3109/00365521.2010.516450. Epub 2010 Sep 7.
5
The role of cytokines in hepatocellular carcinoma.细胞因子在肝细胞癌中的作用。
J Leukoc Biol. 2006 Dec;80(6):1197-213. doi: 10.1189/jlb.0506297. Epub 2006 Aug 31.
6
Individualized precision treatment: Targeting TAM in HCC.个体化精准治疗：肝癌中的 TAM 靶向治疗。
Cancer Lett. 2019 Aug 28;458:86-91. doi: 10.1016/j.canlet.2019.05.019. Epub 2019 May 24.
7
8
The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma.Wnt/β-catenin 通路作为人肝细胞癌的治疗靶点。
Clin Res Hepatol Gastroenterol. 2011 Nov;35(11):709-13. doi: 10.1016/j.clinre.2011.05.010. Epub 2011 Jul 21.
9
Can hepatocellular carcinoma be treated by Yondelis through targeting both tumor cells and tumor-associated macrophages?依托泊苷能否通过靶向肿瘤细胞和肿瘤相关巨噬细胞来治疗肝细胞癌？
Hepatogastroenterology. 2010 Jan-Feb;57(97):114-6.
10
Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially.肝细胞癌中髓源性抑制细胞亚群差异性表达趋化因子和趋化因子受体。
Int Immunopharmacol. 2015 Jun;26(2):314-21. doi: 10.1016/j.intimp.2015.04.010. Epub 2015 Apr 16.
引用本文的文献
1
Advances in Tumor Microenvironment and Immunotherapeutic Strategies for Hepatocellular Carcinoma.肝细胞癌的肿瘤微环境与免疫治疗策略进展
Oncol Res. 2025 Aug 28;33(9):2309-2329. doi: 10.32604/or.2025.063719. eCollection 2025.
2
CX3CR1+ macrophages interact with HSCs to promote HCC through CD8+ T-cell suppression.CX3CR1+巨噬细胞与肝星状细胞相互作用，通过抑制CD8+ T细胞来促进肝癌。
Hepatology. 2025 Sep 1;82(3):655-668. doi: 10.1097/HEP.0000000000001021. Epub 2024 Jul 19.
3
Liver immunology: Biological role and clinical significance.肝脏免疫学：生物学作用及临床意义。
World J Hepatol. 2025 Jul 27;17(7):107541. doi: 10.4254/wjh.v17.i7.107541.
4
Distinct Roles of HHLA2 and PD-L1 in the Immune Cell and Prognosis of Hepatocellular Carcinoma.HHLA2和PD-L1在肝细胞癌免疫细胞及预后中的不同作用
J Hepatocell Carcinoma. 2025 Jul 25;12:1633-1645. doi: 10.2147/JHC.S513033. eCollection 2025.
5
Myeloid TGF-β signaling shapes liver macrophage heterogeneity and metabolic liver disease pathogenesis.髓系转化生长因子-β信号传导塑造肝脏巨噬细胞异质性和代谢性肝病发病机制。
JHEP Rep. 2025 Jun 19;7(8):101488. doi: 10.1016/j.jhepr.2025.101488. eCollection 2025 Aug.
6
Profiling of the tumor-associated microbiome in patients with hepatocellular carcinoma.肝细胞癌患者肿瘤相关微生物群的分析
Gut Pathog. 2025 Jul 10;17(1):53. doi: 10.1186/s13099-025-00727-y.
7
Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy.肝细胞癌中的免疫微环境：从发病机制到免疫治疗
Cell Mol Immunol. 2025 Jun 11. doi: 10.1038/s41423-025-01308-4.
8
ATP13A2 as a prognostic biomarker and its correlation with immune infiltration in cervical cancer: A retrospective study.ATP13A2作为宫颈癌的预后生物标志物及其与免疫浸润的相关性：一项回顾性研究。
J Cell Mol Med. 2025 Apr;29(7):e70097. doi: 10.1111/jcmm.70097.
9
Role of immune cell interactions in alcohol-associated liver diseases.免疫细胞相互作用在酒精性肝病中的作用。
Liver Res. 2024 Jun 10;8(2):72-82. doi: 10.1016/j.livres.2024.06.002. eCollection 2024 Jun.
10
Novel insights into the impact of liver inflammatory responses on primary liver cancer development.关于肝脏炎症反应对原发性肝癌发展影响的新见解。
Liver Res. 2023 Feb 3;7(1):26-34. doi: 10.1016/j.livres.2023.01.001. eCollection 2023 Mar.
本文引用的文献
1
Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. alternatively 激活的（M2）巨噬细胞促进肝癌的生长和侵袭。
J Hepatol. 2015 Mar;62(3):607-16. doi: 10.1016/j.jhep.2014.10.029. Epub 2014 Oct 30.
2
Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells.肿瘤相关巨噬细胞产生白细胞介素6并通过信号转导和转录激活因子3（STAT3）发出信号，以促进人肝癌干细胞的扩增。
Gastroenterology. 2014 Dec;147(6):1393-404. doi: 10.1053/j.gastro.2014.08.039. Epub 2014 Aug 30.
3
Tumor-associated macrophages: from mechanisms to therapy.肿瘤相关巨噬细胞：从机制到治疗
Immunity. 2014 Jul 17;41(1):49-61. doi: 10.1016/j.immuni.2014.06.010.
4
Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma.肿瘤相关巨噬细胞通过转化生长因子-β1 诱导的上皮-间充质转化促进肝癌中的癌症干细胞样特性。
Cancer Lett. 2014 Oct 1;352(2):160-8. doi: 10.1016/j.canlet.2014.05.008. Epub 2014 Jun 2.
5
Role of estrogen in hepatocellular carcinoma: is inflammation the key?雌激素在肝细胞癌中的作用：炎症是关键吗？
J Transl Med. 2014 Apr 8;12:93. doi: 10.1186/1479-5876-12-93.
6
Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2.髓源性抑制细胞通过诱导 microRNA101 和抑制共抑制因子 CtBP2 来增强癌细胞的干性。
Immunity. 2013 Sep 19;39(3):611-21. doi: 10.1016/j.immuni.2013.08.025. Epub 2013 Sep 5.
7
Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression.叉头框蛋白 Q1 通过反式激活 ZEB2 和 VersicanV1 的表达促进肝癌转移。
Hepatology. 2014 Mar;59(3):958-73. doi: 10.1002/hep.26735. Epub 2014 Feb 6.
8
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.在不同的肝癌小鼠模型中髓源性抑制细胞的积累和功能调节。
J Hepatol. 2013 Nov;59(5):1007-13. doi: 10.1016/j.jhep.2013.06.010. Epub 2013 Jun 22.
9
Increased circulating Lin(-/low) CD33(+) HLA-DR(-) myeloid-derived suppressor cells in hepatocellular carcinoma patients.肝癌患者循环中 Lin(-/low) CD33(+) HLA-DR(-) 髓系来源抑制细胞增多。
Hepatol Res. 2014 Jun;44(6):639-50. doi: 10.1111/hepr.12167. Epub 2013 Jul 10.
10
Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.肝癌患者中 GARP(+)CTLA-4(+)Foxp3(+) T 调节细胞和髓源抑制细胞的频率较高与 T 细胞功能受损有关。
Cancer Res. 2013 Apr 15;73(8):2435-44. doi: 10.1158/0008-5472.CAN-12-3381. Epub 2013 Feb 19.
Zotero 插件